CD274 and Familial prostate cancer: The data obtained from prostate cancer and colorectal cancer models suggest that inhibiting the release of PD-L1 in exosomes could be a promising treatment strategy for overcoming resistance to immune checkpoint inhibitors (Poggio et al., 2019).